- Home
- BCLI vs HOOK Comparison
BCLI vs HOOK Comparison
Compare BCLI & HOOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCLI
- HOOK
- Stock Information
- Founded
- BCLI 2000
- HOOK 2011
- Country
- BCLI United States
- HOOK United States
- Employees
- BCLI N/A
- HOOK N/A
- Industry
- BCLI Biotechnology: Biological Products (No Diagnostic Substances)
- HOOK Biotechnology: Pharmaceutical Preparations
- Sector
- BCLI Health Care
- HOOK Health Care
- Exchange
- BCLI Nasdaq
- HOOK Nasdaq
- Market Cap
- BCLI 9.8M
- HOOK 9.3M
- IPO Year
- BCLI N/A
- HOOK 2019
- Fundamental
- Price
- BCLI $1.08
- HOOK $1.25
- Analyst Decision
- BCLI Strong Buy
- HOOK Buy
- Analyst Count
- BCLI 1
- HOOK 4
- Target Price
- BCLI $30.00
- HOOK $10.67
- AVG Volume (30 Days)
- BCLI 473.4K
- HOOK 62.9K
- Earning Date
- BCLI 08-13-2025
- HOOK 08-07-2025
- Dividend Yield
- BCLI N/A
- HOOK N/A
- EPS Growth
- BCLI N/A
- HOOK N/A
- EPS
- BCLI N/A
- HOOK N/A
- Revenue
- BCLI N/A
- HOOK $9,351,000.00
- Revenue This Year
- BCLI N/A
- HOOK N/A
- Revenue Next Year
- BCLI N/A
- HOOK N/A
- P/E Ratio
- BCLI N/A
- HOOK N/A
- Revenue Growth
- BCLI N/A
- HOOK N/A
- 52 Week Low
- BCLI $0.72
- HOOK $0.72
- 52 Week High
- BCLI $6.45
- HOOK $6.77
- Technical
- Relative Strength Index (RSI)
- BCLI 43.20
- HOOK 38.94
- Support Level
- BCLI $1.08
- HOOK $1.23
- Resistance Level
- BCLI $1.32
- HOOK $1.30
- Average True Range (ATR)
- BCLI 0.10
- HOOK 0.06
- MACD
- BCLI -0.01
- HOOK -0.03
- Stochastic Oscillator
- BCLI 4.00
- HOOK 5.97
About BCLI Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
About HOOK HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in partnership with Gilead.